{"id":13788,"date":"2004-06-23T00:00:00","date_gmt":"2004-06-23T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/uncategorized\/m006-mtg061\/"},"modified":"2019-03-01T15:05:27","modified_gmt":"2019-03-01T15:05:27","slug":"m006-mtg061","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/","title":{"rendered":"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials"},"content":{"rendered":"<p>  <b>Featured Conference<\/b> <\/p>\n<p>     <b><a href=\"http:\/\/pharmedassociates.com\/marketing.asp#p177\">Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials<\/a><\/b><br \/>   June 23-25, 2004 \u0095 The Inn at Union League, Philadelphia, PA   <\/p>\n<p> <a href=\"exhib.asp?contitle=Maximizing~the~Value~of~Investigator-Initiated~Post-Marketing~Clinical~Trials&amp;item=s\" class=\"links\">Request Information on Sponsorship Opportunities<\/a><br \/><a href=\"exhib.asp?contitle=Maximizing~the~Value~of~Investigator-Initiated~Post-Marketing~Clinical~Trials&amp;item=e\" class=\"links\">Request Information on Exhibitor Opportunities<\/a><\/p>\n<p>  Investigator-initiated Trials are on the rise and <b>sponsor spending on post-marketing clinical grants is higher than ever before.<\/b> While most companies are doing these types of trials, not all of them are doing them in the most efficient or cost-effective manner.  However, while budgets are being continually trimmed, it\u0092s important for companies to wisely invest resources in these trials.  Moreover, some companies still fail to get the most value from these trials, even after repeated attempts to do them successfully.   <\/p>\n<p> The <b>legal and regulatory hurdles<\/b> are another major pitfall to investigator-initiated trials.  Recent legislation and newly revised guidance documents for the pharmaceutical industry are being introduced regularly in light of the latest anti-kickback statutes.  Pharmaceutical companies must carefully navigate the guidelines to ensure a successful outcome in these investigator-initiated studies.   <\/p>\n<p> We\u0092ve created this <b>leading-edge event<\/b> based on comprehensive research into the most pressing issues facing pharmaceutical companies today in their investigator-initiated studies.  Hear from industry experts on how to:    <\/p>\n<ul>\n<li><b>Bypass regulatory pitfalls<\/b> that might initiate an investigation of your organization <\/li>\n<li>Choose the <b>best trial design<\/b> that fits your intended outcomes <\/li>\n<li>Collect the best and most <b>relevant data<\/b> in your trials <\/li>\n<li>Ensure a <b>rewarding relationship<\/b> with clinical investigators <\/li>\n<li>Expand product visibility through case studies of <b>oncology IITs<\/b> <\/li>\n<\/ul>\n<p> <b> Plus \u0096 Get the Most Out of Your Learning Experience and<br \/> Register for the Half-Day Interactive Pre-Conference Workshops <\/b> <\/p>\n<p>  <b>Managing Interactions between Pharmaceutical Manufacturers and Healthcare Professionals<\/b> highlights the best ways in which pharmaceutical companies and investigators can communicate, without fear of violating regulatory constraints.   <\/p>\n<p> And<\/p>\n<p> <b>Benefit from the Expertise of Our Top-Notch Faculty<\/b>  <\/p>\n<p> Susan Brousseau <i>(invited)<\/i><br \/> Oncology National Director of Scientific Affairs<br \/><b>ASTRAZENECA PHARMACEUTICALS<\/b><\/p>\n<p>  Jane Chin, PhD<br \/> Independent Consultant, Founder<br \/><b>MSL QUARTERLY<\/b><\/p>\n<p>  W. David Dawson, PhD<br \/> Dir. of Medical Information and Science Liaisons<br \/> Global Head of Field Medical Affairs<br \/><b>EMD PHARMACEUTICALS<\/b><\/p>\n<p>  John P. Fruehauf, MD, PhD<br \/> Associate Professor of Clinical Medicine<br \/> Chao Family Comprehensive Cancer Center<br \/><b>UNIVERSITY OF CALIFORNIA IRVINE<\/b><\/p>\n<p>  Stanley B. Garbus, MD, MPH<br \/> Co-Founder and Chief Medical Officer<br \/><b>SENTRX<\/b><\/p>\n<p>  Richard Gliklich, MD<br \/> President and CEO<br \/><b>OUTCOME<\/b><br \/>  John T. Kelly, MD, PhD<br \/><i>formerly<\/i> Sr. VP, Scientific &amp; Regulatory Affairs<br \/><b>PhRMA<\/b><\/p>\n<p>  Charles Laudadio, MD, MBA<br \/> Director, Medical &amp; Regulatory Affairs<br \/><b>J &amp; J \/ MCNEIL SPECIALTY PHARMACEUTICALS<\/b><\/p>\n<p>  Alan Minsk<br \/> Partner &amp; Leader, Food and Drug Law<br \/><b>ARNALL GOLDEN GREGORY LLP<\/b><\/p>\n<p>  Charles Pierce, MD, PhD, CPI<br \/> Adj. Professor, Pharmaceutical Sciences<br \/><b>UNIVERSITY OF CINCINNATI<\/b><\/p>\n<p>  James Sheehan<br \/> US Attorney <br \/><b>DEPARTMENT OF JUSTICE<\/b><\/p>\n<p>  <\/p>\n<p> Visit the <a href=\"http:\/\/pharmedassociates.com\/marketing.asp#p177\">conference website<\/a>.  <\/p>\n<\/p>\n<p>  <a href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/pm-mtgs.html\"><i>Return to list of conferences&#8230;<\/i><\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigator-initiated Trials are on the rise and sponsor spending on post-marketing clinical grants is higher than ever before. While most companies are doing these types of trials, not all of them are doing them in the most efficient or cost-effective manner. However, while budgets are being continually trimmed, it\u0092s important for companies to wisely invest resources in these trials. Moreover, some companies still fail to get the most value from these trials, even after repeated attempts to do them successfully.<\/p>\n","protected":false},"author":2,"featured_media":13101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1203],"tags":[],"topic":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"Investigator-initiated Trials are on the rise and sponsor spending on post-marketing clinical grants is higher than ever before. While most companies are doing these types of trials, not all of them are doing them in the most efficient or cost-effective manner. However, while budgets are being continually trimmed, it\u0092s important for companies to wisely invest resources in these trials. Moreover, some companies still fail to get the most value from these trials, even after repeated attempts to do them successfully.\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2004-06-23T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-03-01T15:05:27+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"744\" \/>\n\t<meta property=\"og:image:height\" content=\"419\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/\",\"name\":\"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2004-06-23T00:00:00+00:00\",\"dateModified\":\"2019-03-01T15:05:27+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/","og_locale":"en_US","og_type":"article","og_title":"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials - Pharma Marketing Network","og_description":"Investigator-initiated Trials are on the rise and sponsor spending on post-marketing clinical grants is higher than ever before. While most companies are doing these types of trials, not all of them are doing them in the most efficient or cost-effective manner. However, while budgets are being continually trimmed, it\u0092s important for companies to wisely invest resources in these trials. Moreover, some companies still fail to get the most value from these trials, even after repeated attempts to do them successfully.","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/","og_site_name":"Pharma Marketing Network","article_published_time":"2004-06-23T00:00:00+00:00","article_modified_time":"2019-03-01T15:05:27+00:00","og_image":[{"width":744,"height":419,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/","name":"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2004-06-23T00:00:00+00:00","dateModified":"2019-03-01T15:05:27+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006-mtg061\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"Maximizing the Value of Investigator-initiated Post-marketing Clinical Trials"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/13788"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=13788"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/13788\/revisions"}],"predecessor-version":[{"id":14016,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/13788\/revisions\/14016"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/13101"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=13788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=13788"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=13788"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=13788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}